The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer
Abstract
Purpose: We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy and assessed its predictive accuracy on independent cases. Patients and Methods: One hundred thirty-three patients with stage I-III breast cancer were included. Pretreatment gene expression profiling was performed with oligonecleotide microarrays on fine-needle aspiration specimens. We developed predictors of pCR from 82 cases and assessed accuracy on 51 independent cases. Results: Overall pCR rate was 26% in both cohorts. In the training set, 56 probes were identified as differentially expressed between pCR versus residual disease, at a false discovery rate of 1%. We examined the performance of 780 distinct classifiers (set of genes + prediction algorithm) in full cross-validation. Many predictors performed equally well. A nominally best 30-probe set Diagonal Linear Discriminant Analysis classifier was selected for independent validation. It showed significantly higher sensitivity (92% v 61%) than a clinical predictor including age, grade, and estrogen receptor status. The negative predictive value (96% v 86%) and area under the curve (0.877 v 0.811) were nominally better but not statistically significant. The combination of genomic and clinical information yielded a predictor not significantly different from the genomic predictor alone. In 31 samples, RNA was hybridized in replicate with resulting predictions that were 97% concordant. Conclusion: A 30-probe set pharmacogenomic predictor predicted pCR to T/FAC chemotherapy with high sensitivity and negative predictive value. This test correctly identified all but one of the patients who achieved pCR (12 of 13 patients) and all but one of those who were predicted to have residual disease had residual cancer (27 of 28 patients).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Elements of Statistical Learning
Hastie, T., Friedman, J., & Tibshirani, R. (2001) · Springer Series in Statistics · doi:10.1007/978-0-387-21606-5 · Cited by 24,162
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Self-citationPolychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Self-citationKuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Theriault, R. L., Singh, G., Binkley, S. M., Sneige, N., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.460 · Cited by 1,330
Self-citationBast, R. C., Ravdin, P., Hayes, D. F., Bates, S., Fritsche, H., Jessup, J. M., Kemeny, N., Locker, G. Y., Mennel, R. G., & Somerfield, M. R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1865 · Cited by 879
Outcome signature genes in breast cancer: is there a unique set?
Ein-Dor, L., Kela, I., Getz, G., Givol, D., & Domany, E. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bth469 · Cited by 802
Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.576 · Cited by 697
Gianni, L., Zambetti, M., Clark, K., Baker, J., Cronin, M., Wu, J., Mariani, G., Rodriguez, J., Carcangiu, M., Watson, D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0818 · Cited by 626
Self-citation
Cited by
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Gene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Self-citationDeconstructing the molecular portraits of breast cancer
Prat, A., & Perou, C. M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2010.11.003 · Cited by 1,343
Taube, J. H., Herschkowitz, J. I., Komurov, K., Zhou, A. Y., Gupta, S., Yang, J., Hartwell, K., Onder, T. T., Gupta, P. B., Evans, K. W., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004900107 · Cited by 1,041
Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 981
A Constrained ℓ1Minimization Approach to Sparse Precision Matrix Estimation
Cai, T., Liu, W., & Luo, X. (2011) · Journal of the American Statistical Association · doi:10.1198/jasa.2011.tm10155 · Cited by 973
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype
Blenkiron, C., Goldstein, L. D., Thorne, N. P., Spiteri, I., Chin, S.-F., Dunning, M. J., Barbosa-Morais, N. L., Teschendorff, A. E., Green, A. R., Ellis, I. O., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-10-r214 · Cited by 948
MAQC Consortium (2010) · Nature Biotechnology · doi:10.1038/nbt.1665 · Cited by 889
“Genomic analysis of a subset of this sequentially accrued patient population were reported previousl”
MethodWeigman, V. J., Chao, H.-H., Shabalin, A. A., He, X., Parker, J. S., Nordgard, S. H., Grushko, T., Huo, D., Nwachukwu, C., Nobel, A., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1846-y · Cited by 902
Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobagyi, G. N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0799 · Cited by 749
Self-citationGene expression profiling in breast cancer: classification, prognostication, and prediction
Reis-Filho, J. S., & Pusztai, L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61539-0 · Cited by 729
Self-citationHatzis, C. (2011) · JAMA · doi:10.1001/jama.2011.593 · Cited by 699
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
Farmer, P., Bonnefoi, H., Anderle, P., Cameron, D., Wirapati, P., Becette, V., André, S., Piccart, M., Campone, M., Brain, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.1908 · Cited by 623
Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
Prat, A., Adamo, B., Cheang, M. C. U., Anders, C. K., Carey, L. A., & Perou, C. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0397 · Cited by 568
Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine
Adir, O., Poley, M., Chen, G., Froim, S., Krinsky, N., Shklover, J., Shainsky‐Roitman, J., Lammers, T., & Schroeder, A. (2020) · Advanced Materials · doi:10.1002/adma.201901989 · Cited by 496
Sotiriou, C., & Piccart, M. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2173 · Cited by 461
Rody, A., Holtrich, U., Pusztai, L., Liedtke, C., Gaetje, R., Ruckhaeberle, E., Solbach, C., Hanker, L., Ahr, A., Metzler, D., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2234 · Cited by 460
Self-citationHow basal are triple‐negative breast cancers?
Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., & Birnbaum, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23518 · Cited by 443
Sieuwerts, A. M., Kraan, J., Bolt, J., van der Spoel, P., Elstrodt, F., Schutte, M., Martens, J. W. M., Gratama, J.-W., Sleijfer, S., & Foekens, J. A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn419 · Cited by 435
GOBO: Gene Expression-Based Outcome for Breast Cancer Online
Ringnér, M., Fredlund, E., Häkkinen, J., Borg, Å., & Staaf, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017911 · Cited by 418
DiMeo, T. A., Anderson, K., Phadke, P., Feng, C., Perou, C. M., Naber, S., & Kuperwasser, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4135 · Cited by 414
Self-citationbc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer
Jézéquel, P., Campone, M., Gouraud, W., Guérin-Charbonnel, C., Leux, C., Ricolleau, G., & Campion, L. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1457-7 · Cited by 407
TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer
de Mingo Pulido, Á., Gardner, A., Hiebler, S., Soliman, H., Rugo, H. S., Krummel, M. F., Coussens, L. M., & Ruffell, B. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.019 · Cited by 388
Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
Ni, M., Chen, Y., Lim, E., Wimberly, H., Bailey, S. T., Imai, Y., Rimm, D. L., Shirley Liu, X., & Brown, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.026 · Cited by 397
Network exploration via the adaptive LASSO and SCAD penalties
Fan, J., Feng, Y., & Wu, Y. (2009) · The Annals of Applied Statistics · doi:10.1214/08-aoas215 · Cited by 397
Basal Breast Cancer: A Complex and Deadly Molecular Subtype
Bertucci, F., Finetti, P., & Birnbaum, D. (2012) · Current Molecular Medicine · doi:10.2174/156652412798376134 · Cited by 394
Kaufmann, M., von Minckwitz, G., Bear, H. D., Buzdar, A., McGale, P., Bonnefoi, H., Colleoni, M., Denkert, C., Eiermann, W., Jackesz, R., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm201 · Cited by 386
Self-citationParadoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer
Birkbak, N. J., Eklund, A. C., Li, Q., McClelland, S. E., Endesfelder, D., Tan, P., Tan, I. B., Richardson, A. L., Szallasi, Z., & Swanton, C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3667 · Cited by 350
Chipster: user-friendly analysis software for microarray and other high-throughput data
Kallio, M. A., Tuimala, J. T., Hupponen, T., Klemelä, P., Gentile, M., Scheinin, I., Koski, M., Käki, J., & Korpelainen, E. I. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-507 · Cited by 348
Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., & Clark, E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3633 · Cited by 344
Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337
“Using the MDACC133 data set (34), overexpression of the CCNE1 gene was identified in 18–30% (6–10/33) of the HER2 cases (Fig.”
MethodAndre, F., Job, B., Dessen, P., Tordai, A., Michiels, S., Liedtke, C., Richon, C., Yan, K., Wang, B., Vassal, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1791 · Cited by 336
Self-citationLuo, J., Schumacher, M., Scherer, A., Sanoudou, D., Megherbi, D., Davison, T., Shi, T., Tong, W., Shi, L., Hong, H., et al. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.57 · Cited by 331
Jetset: selecting the optimal microarray probe set to represent a gene
Li, Q., Birkbak, N. J., Gyorffy, B., Szallasi, Z., & Eklund, A. C. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-474 · Cited by 324
A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes
Haibe-Kains, B., Desmedt, C., Loi, S., Culhane, A. C., Bontempi, G., Quackenbush, J., & Sotiriou, C. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr545 · Cited by 313
Iwamoto, T., Booser, D., Valero, V., Murray, J. L., Koenig, K., Esteva, F. J., Ueno, N. T., Zhang, J., Shi, W., Qi, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2574 · Cited by 288
Self-citationA gene expression signature identifies two prognostic subgroups of basal breast cancer
Sabatier, R., Finetti, P., Cervera, N., Lambaudie, E., Esterni, B., Mamessier, E., Tallet, A., Chabannon, C., Extra, J.-M., Jacquemier, J., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0897-9 · Cited by 290
A refined molecular taxonomy of breast cancer
Guedj, M., Marisa, L., de Reynies, A., Orsetti, B., Schiappa, R., Bibeau, F., MacGrogan, G., Lerebours, F., Finetti, P., Longy, M., et al. (2012) · Oncogene · doi:10.1038/onc.2011.301 · Cited by 287
Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer
Symmans, W. F., Hatzis, C., Sotiriou, C., Andre, F., Peintinger, F., Regitnig, P., Daxenbichler, G., Desmedt, C., Domont, J., Marth, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4273 · Cited by 282
Self-citationAlmendro, V., Cheng, Y.-K., Randles, A., Itzkovitz, S., Marusyk, A., Ametller, E., Gonzalez-Farre, X., Muñoz, M., Russnes, H. G., Helland, Å., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.041 · Cited by 274
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
Knauer, M., Mook, S., Rutgers, E. J. T., Bender, R. A., Hauptmann, M., van de Vijver, M. J., Koornstra, R. H. T., Bueno-de-Mesquita, J. M., Linn, S. C., & van ’t Veer, L. J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0814-2 · Cited by 267
Balko, J. M., Cook, R. S., Vaught, D. B., Kuba, M. G., Miller, T. W., Bhola, N. E., Sanders, M. E., Granja-Ingram, N. M., Smith, J. J., Meszoely, I. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2795 · Cited by 262
Benson, J. R., Jatoi, I., Keisch, M., Esteva, F. J., Makris, A., & Jordan, V. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60316-0 · Cited by 261
ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth
Zhang, S., Chen, L., Cui, B., Chuang, H.-Y., Yu, J., Wang-Rodriguez, J., Tang, L., Chen, G., Basak, G. W., & Kipps, T. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031127 · Cited by 260
Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer
Ross, J. S., Hatzis, C., Symmans, W. F., Pusztai, L., & Hortobágyi, G. N. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0248 · Cited by 259
Self-citationHerschkowitz, J. I., He, X., Fan, C., & Perou, C. M. (2008) · Breast Cancer Research · doi:10.1186/bcr2142 · Cited by 255
Klein, M. L., Francis, P. J., Rosner, B., Reynolds, R., Hamon, S. C., Schultz, D. W., Ott, J., & Seddon, J. M. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.01.036 · Cited by 172
Caveats and pitfalls of ROC analysis in clinical microarray research (and how to avoid them)
Berrar, D., & Flach, P. (2012) · Briefings in Bioinformatics · doi:10.1093/bib/bbr008 · Cited by 136
Kim, H. K., Choi, I. J., Kim, C. G., Kim, H. S., Oshima, A., Michalowski, A., & Green, J. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016694 · Cited by 135
Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy
Andre, F., & Pusztai, L. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0636 · Cited by 134
Self-citationWang, C., Uray, I. P., Mazumdar, A., Mayer, J. A., & Brown, P. H. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1925-0 · Cited by 59
(2011) · Europe PMC (PubMed Central) · Cited by 55
MRAS: A Close but Understudied Member of the RAS Family
Young, L. C., & Rodriguez-Viciana, P. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a033621 · Cited by 53
Edlund, K., Madjar, K., Lebrecht, A., Aktas, B., Pilch, H., Hoffmann, G., Hofmann, M., Kolberg, H.-C., Boehm, D., Battista, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2662 · Cited by 24
Castro, A. F., Campos, T., Babcock, J. T., Armijo, M. E., Martínez‐Conde, A., Pincheira, R., & Quilliam, L. A. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23458 · Cited by 22
Metadata
- Authors
- Hess, K. R., Anderson, K., Symmans, W. F., Valero, V., Ibrahim, N., Mejia, J. A., Booser, D., Theriault, R. L., Buzdar, A. U., Dempsey, P. J., Rouzier, R., Sneige, N., Ross, J. S., Vidaurre, T., Gómez, H. L., Hortobagyi, G. N., & Pusztai, L.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-09-10
- Volume
- 24
- Issue
- 26
- Pages
- 4236-4244
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2154899482
- Cited by
- 721
- References
- 26
- FWCI
- 23.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.